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Abstract
Background: Better surgical techniques, chemotherapy and biological therapy have improved survival in patients
with colorectal cancer (CRC), most markedly in younger patients. About half of patients over 70 years receive dose
reductions or early treatment discontinuation of the planned adjuvant or first-line treatment due to side effects.
The Comprehensive Geriatric Assessment (CGA) is a multidisciplinary evaluation of an elderly individual’s health
status. This assessment in older patients with cancer can predict survival, chemotherapy toxicity and morbidity.
Methods: This randomized phase II trial (GERICO) is designed to investigate whether comprehensive geriatric assessment
and intervention before and during treatment with chemotherapy in frail elderly patients with stages II–IV CRC will
increase the number of patients completing chemotherapy. All patients ≥70 years in whom chemotherapy for
CRC is planned to start at Herlev and Gentofte Hospital are screened for frailty using the G8 questionnaire at
the first visit to the outpatient clinic. The G8 questionnaire is a multi-domain screening tool to identify frail or
vulnerable patients at risk of increased toxicity and morbidity. Frail patients are offered inclusion and are then
randomized to two groups (the intervention group and the control group). Patients in the intervention group
receive a full geriatric assessment of comorbidity, medication, psycho-cognitive function, physical, functional
and nutrition status, and interventions are undertaken on identified health issues. Simultaneously, they are
treated for their cancer according to international guidelines. Patients in the control group receive the same
chemotherapy regimens and standard of care. Primary outcome is number of patients completing scheduled
chemotherapy at starting dose. Secondary outcomes are dose reductions, treatment delays, toxicity, time to
recurrence, survival, cancer-related mortality and quality of life.
Discussion: This ongoing trial is one of the first to evaluate the effect of geriatric intervention in frail elderly
patients with CRC. The trial will provide new and valuable knowledge about whether it is beneficial for the
elderly patient undergoing chemotherapy to be treated simultaneously by a geriatrician.
Trial registration: ClinicalTrials.gov ID: NCT02748811. The trial was registered retrospectively; registration date
04/28/2016.
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Background
The incidence of colorectal cancer (CRC) increases with
age [1], and as populations are getting older [2], an in-
creasing number of elderly patients will be diagnosed
with CRC. In recent years, mortality has decreased in
patients with CRC due to better surgical techniques,
chemotherapy and new biological therapy, but in elderly
patients, the mortality remains higher than in younger
patients [3, 4].
Adjuvant chemotherapy after surgery for stages II and
III colon cancer (CC) with 5-fluorouracil (5-FU) [5, 6] or
capecitabine [7, 8] reduces the recurrence rate and im-
proves overall survival (OS). The evidence for the rec-
ommendation of adjuvant chemotherapy in rectal cancer
is sparse, but one meta-analysis supports the use of 5-
FU-based postoperative treatment [9]. For patients older
than 70 years, adjuvant treatment also prolongs time to
recurrence [10], and OS is higher in CRC patients
>75 years receiving adjuvant chemotherapy compared to
patients not treated with chemotherapy [11–13]. There
are divergent results in elderly (defined as age > 70 years)
regarding the addition of oxaliplatin to 5-FU (FOLFOX)
or capecitabine treatment (CAPEOX) on disease-free
survival (DFS) and OS [14–16]. However, combination
chemotherapy is considered standard therapy for pa-
tients with stage III CRC, but the beneficial effect for
elderly patients and patients with stage II CC remains
controversial [5, 17].
Although the benefit of a least single-agent treatment
seems to be the same for elderly and younger patients in
clinical trials, elderly patients are less frequently treated
[18]. In a study reported by Sanoff HK, 63% of patients
aged 75–79 years with CC stage III received adjuvant
chemotherapy, whereas only 14% of patients ≥85 years
received chemotherapy [11]. Elderly patients do not
receive adjuvant treatment because of high age, co-
morbidity and poor performance status (PS) [12], but
this could also be due to lack of social support and
concerns regarding toxicity and efficiency. The underuse
of this potentially lifesaving treatment may explain a
higher prevalence of recurrence and the higher mortality
seen in the elderly with CRC [4]. About half of patients
over 70 years receive dose reductions or early treatment
discontinuation of the planned treatment due to severe
side effects [12].
For patients with metastatic CRC (mCRC), treated
with combinations of chemotherapy drugs (5-FU, cape-
citabine, oxaliplatin or irinotecan) and new biological
drugs in clinical trials, the median OS has increased
from 6 to 8 months to about 24 months over the last
decades [4, 19]. But, in clinical practice, the median
survival is only 10–11 months, mainly due to poor OS
in elderly patients and patients with low PS who do not
receive any treatment [20].
In elderly patients, irinotecan as second-line therapy
has the same efficacy as that seen in younger patients,
but gives an increased risk of grades 3–4 neutropenia
and diarrhea. [21]. Irinotecan/5-FU combinations are
well tolerated and their efficacy is similar to that seen in
younger patients [22].
Retrospective studies suggest that combination chemo-
therapy for elderly patients with mCRC is associated
with longer progression-free survival (PFS) [23], even if
71% of all patients with CAPEOX received dose reduc-
tions. In another study of elderly and frail patients, no
significant improvement was seen when reduced doses
of oxaliplatin were added to capecitabine or 5-FU [24].
In elderly patients with mCRC, adding bevacizumab to
standard chemotherapy improves PFS and OS [25, 26].
However, an increase in thromboembolic events is ob-
served in patients >65 years [25, 27, 28]. For cetuximab
and panitumumab, efficacy and safety are similar for pa-
tients ≤65 and >65 years [29]. Single-agent (off-label)
panitumumab has been shown to be an effective and
well-tolerated first-line treatment for frail elderly pa-
tients deemed unfit for chemotherapy [30].
Geriatric oncology
Oncologists and geriatricians have begun to cooperate to
individualize and improve treatment for elderly patients
with cancer [31]. Elderly vulnerable patients are at high
risk of severe toxicity [32]. During the last decade, there
has therefore been an increased focus on the importance
of individual patient assessment before treatment deci-
sions are made. Chronological age per se should not be an
exclusion criterion for adjuvant or palliative chemotherapy
[33–35]. Comorbidity and PS more than age alone influ-
ence treatment outcomes for both patients in adjuvant
[36] and palliative therapy [23, 37]. The Comprehensive
Geriatric Assessment (CGA) is a multidisciplinary com-
prehensive evaluation of an elderly individual’s functional
status, physical performance, comorbidity, polypharmacy,
cognitive and emotional function, nutritional status and
need of social support [38, 39]. CGA in older patients with
cancer can predict survival, chemotherapy toxicity and
morbidity [40–42]. The assessment can detect unknown
geriatric problems and lead to change in treatment strat-
egy for 20% to 49% of patients [43, 44]. To assess all those
important factors, there is a need for a multidisciplinary
approach in decision making, before and during treatment
with chemotherapy, in elderly patients with CRC [31, 35].
Geriatric frailty assessment can predict 1- and 5-year
survival in patients after surgery for CRC, and the
impact of frailty on 5-year survival is comparable with
the impact of TNM stage [45]. Interventions on identi-
fied health issues found by the CGA could reduce the
side effects and thus increase the number of patients
who complete chemotherapy. The supportive care could
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also improve coping strategies in dealing with adverse
events and thereby improve treatment compliance. This
could increase survival of the patients. In a recent ran-
domized study, the impact of geriatric intervention on
tolerance to chemotherapy in elderly patients
(age > 70 years) was investigated. The patients who re-
ceived CGA in the intervention group (N = 46) were
more likely to complete planned chemotherapy without
dose modifications, but there was no difference in grade
3+ toxicity between the two groups [46].
Screening for frailty
CGA is considered as the most appropriate way to
examine the overall health situation of the elderly pa-
tient, but it is time consuming and not required for all
patients, and other frailty screenings tools have been de-
veloped and validated. In the recommendations from the
International Society for Geriatric Oncology (SIOG)
from June 2014 [47], the G8 questionnaire is found to
be the more or equally sensitive than other screening
tools compared to CGA. For patients with an abnormal
G8 score (≤ 14/17), full CGA is recommended [48].
Geriatric intervention in non-oncological settings
The effect of geriatric intervention in patients undergo-
ing chemotherapy for CRC has not been fully investi-
gated. However, there is evidence for a beneficial effect
of geriatric assessment for elderly admitted to hospitals
for medical conditions. In a meta-analysis of randomized
trials, CGA after appropriate interventions during
hospitalization increased the likelihood of being alive
and living at home 6 months after hospital discharge
[49]. The beneficial effect was greatest for geriatric
wards, but geriatric teams had also a positive effect.
Several studies have evaluated the cooperation be-
tween geriatricians and surgeons from different special-
ties, and a beneficial effect in terms of cost reduction
and treatment outcomes was found, e.g. in elderly pa-
tients with hip fractures randomized to comprehensive
geriatric care compared to usual orthopedic care, 4-
month mobility improves [50]. Multi-disciplinary pre-
operative CGA with post-operative in-ward follow-up by
geriatricians in elderly patients at risk of complications
due to elective orthopedic surgery decreased the risk of
complications and reduced length of hospital stay [51].
For elderly patients undergoing elective orthopedic, uro-
logical or gastrointestinal surgery, a preoperative CGA
led to fewer cancelled procedures, a decrease in postop-
erative complications and a reduced length of stay [52].
To our knowledge, there are no intervention studies
evaluating the beneficial effect of geriatric intervention
on chemotherapy completion in patients undergoing
chemotherapy for CRC. No such studies are described
on clinical trials.gov (search July 15, 2016). The present
trial will therefore provide new and valuable knowledge
about whether it is beneficial for the elderly patient with
CRC to be simultaneously treated by a geriatrician.
There is no evidence for the effect of the full geriatric
intervention in patients with CRC undergoing chemother-
apy; however, different parts of the geriatric assessment
have been shown to be predictive, and intervention has
been shown to be beneficial.
Physical exercise
In the last decade, there has been an increased focus on
physical performance, exercise and their relation with a
diagnosis of CC, treatment outcomes and quality of life
during and after chemotherapy. Physical activity pre-
vents risk of CC [53], and several studies suggest that
physical activity after cancer diagnosis increases DFS
and OS [54], and it is found to be associated with CC-
and CRC-specific mortality [55, 56]. In mouse models,
physical exercise reduces tumor growth, probably by in-
creasing immune cell infiltration [57]. Jung et al. found
that decreased muscle mass at the start of treatment was
significantly associated with toxicity grades 3 to 4 in pa-
tients undergoing adjuvant chemotherapy [58]. Others
have reported the beneficial effect of physical training on
quality of life and fatigue during chemotherapy [59, 60].
In a recent study of 33 patients with CC, an 18-week ex-
ercise program significantly reduced physical and general
fatigue [61]. In patients undergoing adjuvant chemother-
apy for CRC, supervised exercise compared to usual care
was superior in improvements of physical activity level,
functional status and QOL, but the patients were youn-
ger than in GERICO (mean 56.5 years) [62]. Among
breast cancer patients undergoing adjuvant treatment,
both moderate to high-intensity exercise and low inten-
sity home training programs resulted in better physical
performance but also less pain and toxicity (e.g. nausea
and vomiting) due to the treatment [63]. In patients
med lung cancer, home-based walking has been shown
to be feasible and have a beneficial effect on anxiety and
depression [64]. In a meta-analysis, Meneses-Echáves et
al. conclude that supervised physical activity interven-
tions reduce cancer-related fatigue and suggest that
combined aerobic and resistance exercise regimens
should be included as a part of rehabilitation in people
diagnosed with cancer [65].
Many elderly patients suffer from sarcopenia, an age-
related decrease in muscle mass and strength leading to
decline in physical performance. Sarcopenia is associated
with falls, disabilities and increased risk of death [66].
Muscle strength is measured with handgrip strength,
with a cut off of 20 kg for women and 30 kg for men
[67]. Muscle mass can be measured with DXA scanning,
and physical performance is assessed by different tests.
Usual gait speed, which is commonly used, is associated
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with OS [68], and a gait speed over 4 m (at a threshold
of 1 m/s) can predict adverse outcomes in community-
dwelling older people [69]. Gait speed is also recom-
mended as a frailty screening test in cancer patients
65 years of age and older [70]. Low handgrip strength
and slow usual gait speed are independently associated
with higher mortality [71].
Nutritional intervention
Loss of weight in patients with cancer is associated with
a poor prognosis [72], and nutritional support to mal-
nourished patients with gastrointestinal cancer is recom-
mended [73]. There are few studies evaluating the effect
of nutrition intervention in cancer patients. In 358 pa-
tients with metastatic or locally advanced gastrointes-
tinal, non-small cell lung cancer or mesothelioma
undergoing chemotherapy, nutritional advice and sup-
plements had no impact on 1-year mortality or quality
of life [74]. In a meta-analysis of 1414 malnourished pa-
tients with different cancers included in 13 randomized
controlled trials, nutritional intervention was found to
be effective in increasing nutritional intake and improv-
ing some aspects of QOL, but the interventions had no
effect on mortality [75]. In a randomized trial of 336 pa-
tients with cancer at risk of malnutrition, dietary coun-
seling increased nutritional intake but had no impact on
mortality, toxicity or other treatment outcomes [76].
The authors suggest that cancer cachexia anti-anabolism
is responsible for the lack of effect.
Methods /Design
Aim
The aim of the study is to investigate whether frail eld-
erly patients (defined as age ≥ 70 years) with stages II–
IV CRC will benefit from full comprehensive geriatric
assessment and intervention before and during treat-
ment with adjuvant or palliative first-line chemotherapy.
We will evaluate whether optimizing all health condi-
tions can increase the number of patients completing
6 months of adjuvant chemotherapy or first-line chemo-
therapy until disease progression.
Hypothesis
Our hypothesis is that geriatric intervention can optimize
the health and functional status of frail elderly patients
with stages II–IV CRC. Due to this geriatric intervention,
more patients will receive the scheduled doses and series
of chemotherapy. As a consequence, the patients will have
a longer OS and an improved quality of life.
Design
The study is an open, randomized, prospective trial per-
formed at the departments of oncology and medicine at
Copenhagen University Hospital, Herlev and Gentofte,
Denmark.
Participants
A total of 140 participants will be included: 70 partici-
pants in the intervention group and 70 participants in
the control group.
All patients ≥70 years [77] who meet the criteria to either
receive adjuvant chemotherapy after surgery for stage III
and high-risk stage II CRC or palliative first-line chemo-
therapy for inoperable or metastatic CRC will be screened
for frailty with the G8 questionnaire [78] at their first visit
to the oncology outpatient clinic. Frail patients, defined as
patients with ≤14/17 points in the G8 questionnaire, will be
offered inclusion in the study. Other inclusion criteria are
PS 0–2 and a life expectancy ≥3 months. All patients must
provide informed signed consent to be eligible for inclusion.
Exclusion criteria are other malignancies during the last
5 years (except basal cell carcinoma, squamous cell carcin-
oma in situ and cervical cancer), and simultaneous partici-
pation in a trial of a medical product. The patients with
recurrence or metastatic disease must not have received
prior adjuvant treatment in the GERICO protocol.
To achieve adequate participant enrolment, the single
center research team notifies the oncologists about all
patients eligible for screening. The research team obtains
informed consent and collects all data.
Randomization
After inclusion, the participants are randomized to ei-
ther the intervention group or the control group. The
randomization is made using ARRACT (A Real-time
Randomization Application for Clinical Trials), a com-
puter program developed and operated by the Depart-
ment of Oncology Clinical Research at Herlev and
Gentofte Hospital. The method used is "Stratified Bal-
anced Allocation Method (n- Treatments)" [79, 80]. In
the randomization, the PS of the patients (0 or 1+), and
chemotherapy treatment (adjuvant or metastatic setting)
are used as stratification variables.
Description of the two groups
The patients in the control group receive standard treat-
ment with 6 months of adjuvant chemotherapy after sur-
gery for CRC or palliative first-line chemotherapy until
disease progression, operation or other scheduled change
in treatment. If the patient has other health problems,
those issues will be assessed either by the oncologist or by
the general practitioner according to standard of care.
The patients in the intervention group also receive
standard treatment with 6 months of adjuvant chemo-
therapy after surgery for CRC or first-line chemotherapy
until disease progression, operation or other scheduled
change of treatment. These patients will simultaneously
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be examined and treated by a geriatrician (CL), who will
assess all other health issues.
Patients in both groups will fill out quality of life ques-
tionnaires (QLQ) prior to the start of chemotherapy,
after 2 months, and at the end of the treatment using
the validated QLQ C30 and QLQ ELD14 questionnaires
from the European Organization for Research and Treat-
ment of Cancer (EORTC). The adverse events are rou-
tinely recorded by the oncologist using the standardized
CTC criteria version 4.0.
Geriatric assessment and intervention
All patients in the intervention group will receive full
geriatric assessment and a clinical examination at start
of chemotherapy, after 2 months, and more frequently if
needed. Invention will be performed on identified issues
(Table 1).
In the present study, all patients in the intervention
group are screened, as part of the geriatric assessment,
with a Jamar Dynamometer for handgrip strength (cut
off 20 kg for women and 30 kg for men) and with a 10-
m gait speed (cut-off 1 m/s). With a test result under
cut off, patients are referred to a standardized physical
exercise program twice weekly at the hospital and home
exercise once weekly for 12 weeks.
Furthermore, the patients in the intervention group
are screened for risk of malnutrition, and the patients
are referred to a dietitian if needed.
Review of patients’ medication lists will be performed
with focus on polypharmacy and interactions [81] and
inappropriate medication based on START STOPP cri-
teria [82].
The oncological treatment
The standard adjuvant chemotherapy is outlined in
Table 2. The standard dose is based on body surface area
(BSA), with a possible 25% primary dose reduction in
frail patients.
Study objectives
Primary outcome
The primary endpoint of the study is the proportion of
patients completing scheduled chemotherapy with the
same dose as at the start of treatment.
Secondary outcomes
Secondary endpoints include adverse events (registered
for every chemotherapy cycle after CTC criteria version
4.0), dose reductions, treatment delays (which follow the
standardized guidelines of the department), DFS, PFS,
OS, CRC mortality and quality of life.
Statistical power and analyzes
The power calculation is made based on the expected
impact of the geriatric intervention. The proportion of
patients who complete the planned treatment is assumed
to increase from 50%, the percentage given in the litera-
ture [12], to 75% after geriatric intervention. With 70 pa-
tients included in each group (total 140 evaluable
patients) such an increase can be detected at a 5% sig-
nificance level with a probability (power) of 87%. The
proportion in the two groups will be compared using a
chi-square test.
Dose intensity (DI), the cumulative given dose com-
pared to planned total dose per week, and relative dose
Table 1 The geriatric assessment performed at the start of treatment
Domain Assessment Possible intervention
Multimorbidity Medical record review
Clinical examination
Treatment or referrals
Medication Assessment of medication list based on
START/STOPP criteria
Discontinuation
Change in dosage
Change in prescription of medication
Psychological function Geriatric depression scale (GDS) Referral to therapy or medication
Cognitive function Minimal Mental State Examination (MMSE) Cognitive evaluation
Medication
Social support
Nutritional status Local nutritional screening based on minimal
nutrition assessment (MNA)
Referral to dietitian
Physical function Gait speed 10 m: (cut off 1 m/s)
Handgrip assessed with the Jamar Dynamometer:
(cut off 20 kg for women and 30 kg for men)
Referral to physiotherapist and
scheduled program
Functional status Activities of daily living (ADL) Instrumental
activities of daily living (IADL)
Social support
Occupational therapy assessment
for equipment needs
Transport support
Laboratory parameters TSH, cbalamin, folat, albumin, vitamin D Treat deficiencies
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intensity (RDI), defined as 100* DI/ planned dose inten-
sity (PDI) (mg/ week), will be analyzed.
DFS is defined as time from surgery to time of
recurrence or death. PFS is defined as time from start of
first-line chemotherapy to date of progression or death
according to RECIST criteria 1.1. OS is defined as time
from surgery or start of first-line treatment to time of
death. CRC mortality will be analyzed in all patients who
are followed until outcome of interest or end of follow-
up using statistical methods for censored time-to-event
data.
All statistical analyzes will be performed by a statisti-
cian (CD). The statistical software package R (http://
www.rproject.org) is used for all analyses. Disease-free
survival, PFS and OS will be estimated with the Kaplan–
Meier method and compared with a log-rank test. Add-
itional subgroup analyses based on chemotherapy regi-
men will be performed if feasible. Missing data will be
handled with multiple imputations.
Discussion
In spite of the high prevalence of CRC and the high inci-
dence of CRC-related mortality, elderly patients are
under-presented in clinical trials [38]. Nevertheless, eld-
erly patients are the largest group of cancer patients,
and their number is rapidly growing.
When treating elderly patients with comorbidity and
poor PS, oncologists today possess a limited number of
treatment options. Due to concerns regarding toxicity
and the lack of guidelines for treating elderly patients,
there is a trend toward less aggressive treatment and ex-
clusion of elderly patients especially in the adjuvant set-
ting, where chemotherapy is potentially lifesaving [83].
There is, however, evidence that chemotherapy is also
effective in elderly patients, and in order to improve the
poorer cancer prognosis, it is of great importance to find
the elderly patients who will profit from chemotherapy
and to perform dose adjustments in case of side effects
[84, 85].
The cooperation between geriatricians and oncologists
in order to individualize and improve treatment for eld-
erly patients with cancer could be the solution. However,
there is a lack of randomized intervention studies that
evaluate the effect of geriatric intervention treatment
outcomes in elderly patients with CRC.
In the present GERICO study, only elderly frail patients
with CRC receiving chemotherapy are included. There
may be a group of patients who are deemed too frail, too
old or to have too much comorbidity to receive chemo-
therapy, which could profit from the geriatric assessment.
An optimization of health conditions in those patients
could bring them into consideration for treatment.
Our long-term aim is to integrate the geriatric func-
tion into the oncology setting. Optimizing the overall
health of elderly patients will potentially allow more in-
tensive treatment, which would lead to increased sur-
vival and a higher quality of life. The project will provide
new and valuable information for better treatment of
frail, elderly patients with CRC.
Table 2 Regimens and doses of chemotherapy
Adjuvant setting
Regimen Drug Dose Frequency
Capecitabine Capecitabine 2000 mg/m2 p.o.
daily for 14 days
Every 3 weeks*
5-FU 5-FU
Calcium folinate
400 mg/m2 i.v.
Infusion 46 h:
2400 mg/ m2 i.v.
400 mg/m2 i.v.
Every 2 weeks**
Capeox Capecitabine
Oxaliplatin
2000 mg/m2 p.o.
daily for 14 days
130 mg/m2 i.v.
Every 3 weeks*
Folfox 5-FU
Calcium folinate
Oxaliplatin
400 mg/m2 i.v.
Infusion 46 h:
2400 mg/ m2 i.v.
400 mg/m2 i.v.
85 mg/m2 i.v.
Every 2 weeks**
Metastatic setting
Regimens Drug Dose Frequency
Capecitabine Capecitabine 2000 mg/m2 p.o.
daily for 14 days
Every 3 weeks*
5-FU 5-FU
Calcium folinate
400 mg/m2 i.v.
Infusion 46 h:
2400 mg/ m2 i.v.
400 mg/m2 i.v.
Every 2 weeks**
Capeox Capecitabine
Oxaliplatin
2000 mg/m2 p.o.
daily for 14 days
130 mg/m2 i.v.
Every 3 weeks*
Folfox 5-FU
Calcium folinate
Oxaliplatin
400 mg/m2 i.v.
Infusion 46 h:
2400 mg/ m2 i.v.
400 mg/m2 i.v.
85 mg/m2 i.v.
Every 2 weeks***
Irinotecan Irinotecan 200 mg/m2 i.v. Every 2 weeks****
Capiri Capecitabine
Irinotecan
1600 mg/m2 p.o.
daily for 14 days
200 mg/m2 i.v.
Every 3 weeks *
Folfiri 5-FU
Calcium folinate
Irinotecan
400 mg/m2 i.v.
Infusion 46 h:
2400 mg/ m2 i.v.
400 mg/m2 i.v.
180 mg/m2 i.v.
Every 2 weeks****
Irox Irinotecan
Oxaliplatin
165 mg/m2 i.v.
85 mg/m2 i.v.
Every 2 weeks****
*maximum 8 series
**maximum 12 series
i.v. intravenous, p.o. per os
*optional addition of bevacizumab 7.5 mg/m2 i.v
**optional addition of bevacizumab 5 mg/m2 i.v
***optional addition of bevacizumab 5 mg/m2 i.v., irinotecan 165 mg/m2 i.v.,
cetuximab 500 mg/m2 i.v., or panitumumab 6 mg/kg i.v
****optional addition of bevacizumab 5 mg/m2 i.v., cetuximab 500 mg/m2 i.v.,
or panitumumab 6 mg/kg i.v
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Trial status
The first participant was included in April 2015. The re-
cruitment period is 2–3 years. The last participant in-
cluded is expected in June 2018. A total of 190 patients
have been screened for frailty with the G8 questionnaire,
and (131) 69% of the patients were frail, a little lower
percentage than seen in other studies [86]. To date, 81
patients have been included. The number of included
patients is lower than expected. One of the reasons is
that 32 patients were not screened at all, since they were
found to be too frail to receive treatment. Of the 131
patients screened frail with the G8 questionnaire, 19
patients did not start any treatment due to performance
status, high age, comorbidity or patients’ refusal (Fig. 1).
An additional five patients were excluded because of
other malignancies. Since the start of the trial, eight
patients that could have been included were missed.
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